In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Eric's career includes extensive work ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Andy Smith is a Certified Financial Planner (CFP®), licensed realtor and educator with over 35 years of diverse ...

Embryonic cell lines were established from sea urchins which recapitulated aspects of the developmental program in vitro and were amenable to lentiviral transduction, providing a scalable platform for ...

Non melanoma skin cancer is cancer that starts in the skin tissue. Most skin cancers are caused by exposure to the sun. Treatments might include surgery, radiotherapy and chemotherapy. There are 2 ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.